CALL - SPRINTER OPEN END - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 02:05:22 2024-07-12 pm EDT | ||
| 5.26 EUR | -13.06% |
|
| Current month | -5.40% | ||
| 1 month | -4.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 5.26 | -13.06% |
| 24-07-11 | 6.05 | +8.04% |
| 24-07-10 | 5.6 | +6.06% |
| 24-07-09 | 5.28 | 0.00% |
| 24-07-08 | 5.28 | +3.53% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 02:05 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV3XT4 |
| ISIN | DE000VV3XT46 |
| Date issued | 2022-06-17 |
| Strike | 173.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.29 € |
|---|---|
| Lowest since issue | 2.02 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
236.8
USD
Average target price
281.3
USD
Spread / Average Target
+18.79%
- Stock Market
- Certificates
- Certificat
